Orchestra BioMed (OBIO) vs Ocugen (OCGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Orchestra BioMed (OBIO) has outperformed Ocugen (OCGN) over the past year, gaining 107.3% versus a loss of 43.2%. Over five years, OBIO leads with a -42.5% price change compared with -88.5% for OCGN. Orchestra BioMed is the larger company by market cap ($344.4 million vs $331.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OBIO | OCGN |
|---|---|---|
| Share price | $5.73 | $0.9774 |
| Market cap | $344.40M | $331.45M |
| 1-day change | +1.24% | -2.26% |
| YTD return | +36.39% | -25.93% |
| 1-year return | +107.33% | -43.18% |
| 5-year return | -42.54% | -88.45% |
| EPS (TTM) | $-0.86 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.50 | $2.73 |
| 52-week low | $2.78 | $0.9601 |
| Distance from 52-week high | -11.85% | -64.13% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +116.93% | +1145.14% |
| Average volume | 299.24K | 5.81M |
| Shares outstanding | 60.11M | 339.11M |
| Employees | 86 | 116 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OBIO has outperformed OCGN by 150.5 percentage points over the past year.
About Orchestra BioMed
OBIO stock →Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
Health Care · Medicinal Chemicals and Botanical Products · 86 employees
About Ocugen
OCGN stock →Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees
OBIO vs OCGN FAQ
Which is bigger, Orchestra BioMed or Ocugen?
Orchestra BioMed (OBIO) is larger, with a market capitalization of $344.40M compared with $331.45M for Ocugen (OCGN).
Which stock has performed better over the past year, OBIO or OCGN?
OBIO returned +107.33% over the past 12 months, compared with -43.18% for OCGN (price return, excluding dividends). Past performance does not predict future results.
Are Orchestra BioMed and Ocugen in the same industry?
Both are in the Health Care sector, but in different industries: Medicinal Chemicals and Botanical Products for Orchestra BioMed and Biotechnology: Biological Products (No Diagnostic Substances) for Ocugen.